Reset filter
Keywords
Prostatic Neoplasms ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

6 Search results.
Relevance Rating New first Old first

Sirolimus in Renal Transplant Patients with Prostate Cancer NCT00922129 - Eligibility Criteria

- 5/29/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00922129

PET, Kidney, Saliva PSMA-Studie Prostatakarzinom NCT0000001 - PET, Niere, Speichel PSMA-Studie Prostatakarzinom NCT0000001

- 7/14/16 - 1 form, 10 itemgroups, 21 items, 2 languages
Itemgroups: Identification, Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 6, Cycle 7, Cycle 8, Saliva
Quelle: PSMA-Studie Prostatakarzinom PD Dr. med. Kambiz Rahbar UKM, Nuklearmedizin Teil: PET, Niere, Speichel

dbGaP phs000942 Use of WGS for Diagnosis and Discovery in the Cancer Genetics Clinic - Eligibility

- 11/27/24 - 5 forms, 1 itemgroup, 1 item, 1 language
Itemgroup: IG.elig
Principal Investigator: Theodora S. Ross, MD, PhD, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA, and Department of Cancer Genetics, UT Southwestern Medical Center, Dallas, TX, USA MeSH: Neoplasms,Breast Neoplasms,Ovarian Neoplasms,Peritoneal Neoplasms,Skin Neoplasms,Esophageal Neoplasms,Thyroid Neoplasms,Urinary Bladder Neoplasms,Endometrial Neoplasms,Fallopian Tube Neoplasms,Melanoma,Testicular Neoplasms,Bile Duct Neoplasms,Lung Neoplasms,Colonic Neoplasms,Adrenocortical Carcinoma,Carcinoma, Renal Cell,Colonic Polyps,Adenomatous Polyposis Coli,Lymphoma, Large B-Cell, Diffuse,Pheochromocytoma,Paraganglioma,Leiomyoma,Hemangioblastoma,Hyperparathyroidism,Pancreatic Neoplasms,Vulvar Neoplasms,Brain Neoplasms,Liver Neoplasms,Kidney Neoplasms,Prostatic Neoplasms,Glioblastoma,Oncocytoma, renal https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000942 Despite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical value of WGS in the cancer genetics clinic is unknown. We performed WGS on members of two cohorts of cancer genetics patients: those with BRCA1/2 mutations (n = 176) and those without (n = 82). Initial analysis of potentially pathogenic variants (PPVs, defined as nonsynonymous variants with allele frequency 1% in ESP6500) in 163 clinically-relevant genes suggested that WGS will provide useful clinical results. This is despite the fact that a majority of PPVs were novel missense variants likely to be classified as variants of unknown significance (VUS). Furthermore, previously reported pathogenic missense variants did not always associate with their predicted diseases in our patients. This suggests that the clinical use of WGS will require large-scale efforts to consolidate WGS and patient data to improve accuracy of interpretation of rare variants. While loss-of-function (LoF) variants represented only a small fraction of PPVs, WGS identified additional cancer risk LoF PPVs in patients with known BRCA1/2 mutations and led to cancer risk diagnoses in 21% of non-BRCA cancer genetics patients after expanding our analysis to 3209 ClinVar genes. These data illustrate how WGS can be used to improve our ability to discover patients' cancer genetic risks. "Reprinted from doi:10.1016/j.ebiom.2014.12.003, with permission from EBioMedicine."

pht004834.v1.p1

1 itemgroup 5 items

pht004835.v1.p1

1 itemgroup 5 items

pht004836.v1.p1

1 itemgroup 16 items

pht004837.v1.p1

1 itemgroup 5 items

Eligibility DRKS00009656 NCT00069745 Prostate Cancer - Eligibility

- 9/20/21 - 1 form, 3 itemgroups, 34 items, 2 languages
Itemgroups: Inclusion criteria, Exclusion criteria, Medical Concepts
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen Inclusion Criteria: - Stage D2 metastatic prostate cancer - Progression after one prior chemotherapy - ECOG Performance status equal / less than 2 - Life expectancy > 3 months - Surgical or medical castration - Adequate bone marrow, hepatic and renal functions - Informed consent Exclusion Criteria: - More than one prior chemotherapy - Prior platinum containing compounds - Prior malignancy - Prior significant RT/radionuclide therapy - Major GI surgery or GI disease affecting absorption - Disease with contraindication to steroids - Brain metastases

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Baseline - CRFs Cabazitaxel Prostate Cancer NCT01308580 Baseline

- 5/12/17 - 1 form, 36 itemgroups, 232 items, 1 language
Itemgroups: Visit Information, Informed Consent, Demography, Informed Consent - Pharmacokinetic, Informed Consent - Pharmacogenomic, Informed Consent - Biomarker (cDNA), Cancer Diagnosis, Health Status, Bone Scan, Operation on prostate, Surgery for androgen ablation, Prior Radiation Therapy, Prior Chemotherapy, Medical or Surgical History, Renal Diseases and Risk, Medication - Nephrotoxicity, Vital Signs, Ophthalmologic Examination, Electrocardiogram, Laboratory Tests Hematology, Laboratory Tests Biochemisty, Urinanalysis, Blood sampling, Tumor Workup, Tumor Assessment - Target Lesions, Tumor Assessment - Non-target Lesion, Bone Scan, Tumor markers, Questionnaire for Cancer Pain, FACT-P Questionnaire, FACT-P Questionnaire: Physical Well-Being, FACT-P Questionnaire - Social/ Family Well-Being, FACT-P Questionnaire - Emotional Well-Being, FACT-P Questionnaire - Functional Well-Being, FACT-P Questionnaire - Additional Concerns, Eligibility for Randomization
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Additional - CRFs Cabazitaxel Prostate Cancer NCT01308580 Additional

- 6/15/17 - 1 form, 17 itemgroups, 113 items, 1 language
Itemgroups: Laboratory Tests Hematology, Laboratory Tests Biochemistry, Urinanalysis, Tumor Markers, Laboratory Tests Unplanned, Vital Signs, Electrocardiogram, Urine dipstick test, Prior and Concomitant Medication, Radiation Therapy, Anti-Cancer Therapy, Operation on prostate, Other Procedures, Renal Failure Investigation, Cystoscopy, Symptomatic Deterioration, Subject Status
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial